Resistance mechanism of ST1571 and its prevention research--review.
- Author:
Xia ZHOU
1
;
Jian HOU
Author Information
1. Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai 200003, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
pharmacology;
Benzamides;
Drug Resistance, Neoplasm;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
drug therapy;
Piperazines;
pharmacology;
Pyrimidines;
pharmacology
- From:
Journal of Experimental Hematology
2004;12(5):713-717
- CountryChina
- Language:Chinese
-
Abstract:
STI571 is a new antileukemia agent targeting BCR-ABL tyrosine kinase and successfully used in treatment of leukemia patients. Despite strong efficacy of the tyrosine kinase inhibitor STI571, resistance has been observed in a significant proportion of leukemia patients. This review focuses on the diverse mechanisms of ST1571 resistance and its preventive measures.
